Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort.
COVID-19
NMV/r
antibodies
antivirals
humoral immune response
immunology
longitudinal cohort
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
30
06
2023
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
epublish
Résumé
Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.
Identifiants
pubmed: 38352152
doi: 10.1093/ofid/ofad625
pii: ofad625
pmc: PMC10863641
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad625Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors report no potential conflicts.